Context Therapeutics is trading at $0.19, down 6.68%, amid a broad risk-off session, the most likely explanation for the decline.
- No new company-specific announcement explaining the November 5 move was identified.
- The latest reported company news was the September CT-202 trial update.
- Biotech ETF XBI was down 5.19%, alongside steep losses in major U.S. indexes.